检查点抑制剂相关免疫不良反应的生物标记物研究进展  

Progress in Biomarkers for Checkpoint Inhibitor-associated Immune Adverse Events

作　　者：马素莲[1] 居瑞雪 戴晓莉 田恩圣 MA Su-lian;JU Rui-xue;DAI Xiao-li;TIAN En-sheng(Department of Clinical Laboratory,the People’s Hospital of Linqu,Linqu 262600,China;Department of Pharmacy,the People’s Hospital of Weifang,Weifang 261000,China;Shandong Academy of Pharmaceutical Sciences,Jinan 250101,China;Shandong Center for Food and Drug Evaluation&Certification,Jinan 250014,China)

机构地区：[1]临朐县人民医院检验科,山东临朐262600 [2]潍坊人民医院检验科,山东潍坊261000 [3]山东省药学科学院,山东济南250101 [4]山东省食品药品审评认证中心,山东济南250014

出　　处：《食品与药品》2021年第4期I0004-I0007,共4页Food and Drug

摘　　要：免疫检查点抑制剂可使多种癌症得到持久缓解,是免疫治疗的重要进展。然而,该类抑制剂相关的免疫性不良反应发生率较高,甚至可能危及生命,因此发现用于检测不良反应的相关生物标记物有重要的临床意义。本文概述了有潜力预测和诊断检查点抑制剂相关免疫不良反应的生物标记物的最新进展,为临床医生评估用药风险和预警不良反应提供参考。Immune checkpoint inhibitors are important advances in immunotherapy which can achieve long-term remission in a variety of cancers.However,immune checkpoint inhibitors often elicit immune-related adverse events which may result in substantial morbidity.So it is of great clinical significance to find biomarkers for the detection of adverse reactions.This paper summarizes the research progress on biomarkers for checkpoint inhibitor-associated immune adverse events to provide reference for clinicians to assess the risk of medication and early warning of adverse reactions.

关 键 词：生物标记 免疫检查点抑制剂 不良反应 安全性 

分 类 号：R979.5[医药卫生—药品]